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Original Research
Presence and Predictive Value of
Obsessive-Compulsive Symptoms
in Anxiety and Depressive Disorders
Pre´sence et valeur pre´dictive de symptoˆmes
obsessionnels-compulsifs dans les troubles anxieux et de´pressifs
Mieke Klein Hofmeijer-Sevink, MD, PhD1, Neeltje M. Batelaan, MD, PhD2,
Harold J. G. M. van Megen, MD, PhD1, Marcel A. van den Hout, PhD3,4,
Brenda W. Penninx, PhD2, Anton J. L. M. van Balkom, MD, PhD2,
and Danielle C. Cath, MD, PhD3,4,5
Abstract
Objective: Obsessive-compulsive symptoms (OCS) co-occur frequently with anxiety and depressive disorders, but the nature
of their relationship and their impact on severity of anxiety and depressive disorders is poorly understood. In a large sample of
patients with anxiety and depressive disorders, we assessed the frequency of OCS, defined as a Young Adult Self-Report Scale–
obsessive-compulsive symptoms score >7. The associations between OCS and severity of anxiety and/or depressive disorders
were examined, and it was investigated whether OCS predict onset, relapse, and persistence of anxiety and depressive disorders.
Methods: Data were obtained from the third (at 2-year follow-up) and fourth wave (at 4-year follow-up) of data collection in
the Netherlands Study of Anxiety and Depression cohort, including 469 healthy controls, 909 participants with a remitted
disorder, and 747 participants with a current anxiety and/or depressive disorder.
Results:OCS were present in 23.6% of the total sample, most notably in those with current combined anxiety and depressive
disorders. In patients with a current disorder, OCS were associated with severity of this disorder. Moreover, OCS predicted
(1) first onset of anxiety and/or depressive disorders in healthy controls (odds ratio [OR], 5.79; 95% confidence interval [CI],
1.15 to 29.14), (2) relapse in those with remitted anxiety and/or depressive disorders (OR, 2.31; 95% CI, 1.55 to 3.46), and (3)
persistence in patients with the combination of current anxiety and depressive disorders (OR, 4.42; 95% CI, 2.54 to 7.70)
within the 2-year follow-up period
Conclusions: OCS are closely related to both the presence and severity of anxiety and depressive disorders and affect their
course trajectories. Hence, OCS might be regarded as a course specifier signaling unfavorable outcomes. This specifier may be
useful in clinical care to adapt and intensify treatment in individual patients.
Abre´ge´
Objectif : Les symptoˆmes obsessionnels-compulsifs (SOC) sont fre´quemment co-occurrents avec les troubles anxieux et
de´pressifs, mais la nature de leur relation et de leur effet sur la gravite´ des troubles anxieux et de´pressifs est mal comprise. Dans
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un vaste e´chantillon de patients souffrant de troubles anxieux et de´pressifs, nous avons e´value´ la fre´quence des SOC, de´finis
comme e´tant un score > 7 a` l’e´chelle d’auto-e´valuation de jeunes adultes des symptoˆmes obsessionnels-compulsifs (YASR-SOC
> 7). Les associations entre les SOC et la gravite´ des troubles anxieux et/ou de´pressifs ont e´te´ examine´es, et la question de
savoir si les SOC pre´disent l’apparition, la rechute ou la persistance des troubles anxieux et de´pressifs a e´te´ e´tudie´e.
Me´thodes : Les donne´es ont e´te´ obtenues du 3e cycle (au suivi de 2 ans) et du 4e cycle (au suivi de 4 ans) de la collecte de
donne´es de la cohorte de l’e´tude ne´erlandaise de l’anxie´te´ et de la de´pression (NESDA), incluant 469 te´moins en sante´, 909
participants en re´mission, et 747 participants souffrant actuellement d’un trouble anxieux et/ou de´pressif.
Re´sultats : Les SOC e´taient pre´sents chez 23,6 % de l’e´chantillon en entier, particulie`rement chez ceux souffrant actuel-
lement de troubles anxieux et de´pressifs combine´s. Chez les patients souffrant d’un trouble actuel, les SOC e´taient associe´s a`
la gravite´ de ce trouble. En outre, les SOC pre´disaient 1) la premie`re apparition des troubles anxieux et/ou de´pressifs chez les
sujets te´moins en sante´ (RC 5,79; IC a` 95 % 1,15 a` 29,14); 2) la rechute chez ceux qui e´taient en re´mission des troubles anxieux
et/ou de´pressifs (RC 2,31; IC a` 95 % 1,55 a` 3,46); et 3) la persistance chez les patients ayant une combinaison des troubles
anxieux et de´pressifs actuels (RC 4,42; IC a` 95 % 2,54 a` 7,70) dans la pe´riode du suivi de 2 ans.
Conclusions : Les SOC sont e´troitement lie´s a` la pre´sence et a` la gravite´ des troubles anxieux et de´pressifs, et influent sur les
trajectoires de leur cours. Les SOC peuvent donc eˆtre estime´s eˆtre un de´terminant du cours des troubles qui signale des
re´sultats de´favorables. Ce de´terminant peut eˆtre utile dans les soins cliniques pour adapter et intensifier le traitement de
patients individuels.
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Both anxiety and depressive disorders are clinically hetero-
geneous, and substantial differences in clinical presentation
and course occur between individual patients. Clinical prac-
tice would benefit from specifiers that distinguish between
mild disorders with favorable course trajectories and severe
disorders with unfavorable course trajectories.
The presence and nature of comorbid disorders may sig-
nal unfavorable outcomes. For example, comorbidity
between anxiety and depressive disorders is associated with
higher illness severity, impaired functioning, unfavorable
course, and poorer treatment outcome.1-6 Likewise, the com-
bination of 2 anxiety disorders in an individual is associated
with higher severity and chronicity compared with single
anxiety disorders.7,8 Further, in obsessive-compulsive disor-
der (OCD), comorbidity with anxiety and/or depressive dis-
orders is associated with higher symptom severity,
chronicity, and negative consequences in daily life.9-12 Even
comorbid symptoms that by themselves do not reach a
threshold to be considered a disorder may have an unfavor-
able impact on the course of the other disorders that they
accompany. The most explicit example is panic attacks.
Based on their negative impact on a variety of disorders,13-15
panic attacks are included as a specifier in the fifth edition of
theDiagnosticManual ofMental Disorders (DSM-5)16 to alert
clinicians to unfavorable outcomes.
Obsessive compulsive symptoms (OCS) occur in 30% to
40% of patients with an anxiety or depressive disorder.4,17
Systematic studies of the impact of OCS on clinical outcome
in anxiety disorders is—to the best of our knowledge—lack-
ing, and studies on OCS and their impact on depressive
disorders are scarce. In depressive disorders, one study has
suggested that OCS are associated with poorer outcome.18
Considering the suggestion from this study that OCS are
associated with anxiety and depression symptom severity
and have a negative impact on their course trajectories, this
would mean that OCS might be a useful specifier signaling
unfavorable outcomes.
Using longitudinal data from the Netherlands Study of
Depression and Anxiety (NESDA), the present study was
undertaken to examine the impact of OCS on anxiety and
depressive disorders. We explored the impact of OCS on
these disorders, above and over potential other confounders.
We assessed the presence of OCS, examined the associations
of OCS with severity of anxiety and/or depressive disorders,
and investigated whether OCS predict onset, relapse, and
persistence of anxiety and depressive disorders. We
hypothesized that OCS are meaningful negative predictors
of course in anxiety and depressive disorders.
Materials and Methods
Procedure
Data were obtained from NESDA. NESDA encompasses a
longitudinal cohort study that has included 2981 adults
(18-65 years of age) at baseline with anxiety disorders (panic
disorder with/without agoraphobia, social phobia, and gen-
eralized anxiety disorder), with depressive disorders (major
depressive disorder, dysthymic disorder), and healthy con-
trols. A detailed description of the NESDA study design can
be found elsewhere.19 In short, the NESDA study aims to
describe the long-term course and consequences of depres-
sive and anxiety disorders in a sample recruited from the
community, primary care settings, and specialized mental
86 The Canadian Journal of Psychiatry 63(2)
health care facilities. Persons with a clinically overt primary
diagnosis of psychosis, posttraumatic stress disorder, or
OCD were not included in the study, as were persons not
fluent in the Dutch language. To study OCS, The Young
Adult Self-Report Scale for obsessive compulsive symp-
toms20 (YASR-OCS) was administered at the 2-year follow-
up wave. Therefore, we used this wave as the baseline
measurement point for the present study.
Approval of the study was granted by the Ethical Review
Boards of all participating centers, and written informed
consent was obtained from all participants.
Sample
As OCS were first assessed at the 2-year follow-up, we used
this wave as the baseline measurement point for the present
study and the 4-year wave of NESDA as the 2-year follow-up
measurement of this study. For the present study, all partici-
pants who enrolled in both the 2-year and the 4-year follow-
up (n¼ 2402) were included. The attrition rate between base-
line and the 2-year wave of NESDA was 13% (n¼ 385). This
attrition was not significantly related to gender and age but to
lower level of education (odds ratio [OR], 0.92; 95% confi-
dence interval [CI], 0.98 to 0.95) and to the presence of an
anxiety (OR, 1.37; 95% CI, 1.23 to 1.54) and/or depressive
disorder (OR, 1.64; 95% CI, 1.41 to 1.90) at baseline.
The attrition rate between the 2-year and 4-year wave of
NESDA was 8% (n ¼ 194).
The 24% attrition rate between baseline and the 4-year
follow-up (n ¼ 579) was not significantly related to gender
and age but to lower level of education (OR, 0.93; 95% CI,
0.89 to 0.97) and to the presence of an anxiety (OR, 1.27;
95% CI, 1.15 to 1.41) and/or depressive disorder (OR, 1.32;
95% CI, 1.1 to 1.6) at baseline.
Participants who had not returned the YASR-OCS ques-
tionnaire (n ¼ 270) and those with too many missing data
(n ¼ 7) were excluded. Thus, the final sample who com-
pleted both time points and returned the YASR-OCS con-
sisted of 2125 participants. Compared with those who were
excluded (n ¼ 277), participants who were included (N ¼
2125) were older (P < 0.001), more frequently female (P ¼
0.04), less educated (P ¼ 0.002), and had more anxiety and/
or depressive disorders (P < 0.001) at our baseline (the
2-year follow-up of NESDA).
Measures
OCS. To assess OCS, the 8-item YASR-OCS was used, which
is a subscale of the YASR20 (see Figure 1 for items). Partici-
pants respond on a 3-point scale (0¼ not true, 1 ¼ somewhat
true or sometimes true, 2 ¼ very true or often true), yielding
scores between 0 and 16 on the YASR-OCS. Incidents of
missing data were very rare (0.5%) and therefore considered
random. These missing data were not imputated. The YASR-
OCS has good psychometric properties as a screener of OCS,
with well-established cut points for the presence or absence of
clinically significant OCS.21 The internal reliability of the
YASR-OCS in our sample was good (Cronbach’s a ¼
0.83). In line with the literature, OCS were regarded as sig-
nificantly present with a score of >7 on the YASR-OCS. This
cutoff has been previously identified as the best cutoff to
predict OCD.21
Diagnostic Status. To diagnose anxiety and depressive disor-
ders, the Composite International Diagnostic Interview (CIDI),
version 2.1, was used, using DSM-IV criteria. The CIDI entails
a structured interview with acceptable reliability and valid-
ity22,23 and was administered by trained research staff.
Healthy controls were defined as participants without a
lifetime history of a DSM-IV axis I diagnosis of an anxiety
or depressive disorder (established using the CIDI). The
patient group in this study who were defined as remitted
was composed of patients with a lifetime history of an anxi-
ety and/or depressive disorder but with no anxiety or depres-
sive disorder within the past 6 months. The sample was not
stratified by an anxiety or depressive disorder in the past,
since recent literature shows that diagnostic instability
between and within depressive and anxiety disorders is high
and recurrence does not solely occur in the specific index
disorders.24 The patient group who were defined as suffer-
ing from a “current depressive disorder” contained partici-
pants with a diagnosis of a major depressive disorder and/or
dysthymia within the past 6 months, and the group with a
“current anxiety disorder” contained participants with a
diagnosis of panic disorder and/or agoraphobia, social pho-
bia, and/or generalized anxiety disorder, respectively,
within the past 6 months. The group defined as “current
comorbid anxiety and depressive disorder” contained parti-
cipants with both a depressive and an anxiety disorder
within the past 6 months.
Covariates. All covariates were assessed at ‘baseline’ of the
present study (i.e. the two-year follow-up measurement of
the NESDA study).
Socio-demographic factors included gender (male/
female), age and years of education.
Severity of anxiety and depressive symptoms. Severity of
anxiety symptoms was assessed with the Beck Anxiety
Inventory (BAI), a widely used 21-item self-report
Item 1 ‘I Cannot get my mind off certain thought’
Item 2 ‘I repeat certain acts over and over’
Item 3 ‘I am afraid I might think or do something bad’
Item 4 ‘I have thoughts that other people think are strange’
Item 5 ‘I do things other people think are strange’
Item 6 ‘I feel I have to be perfect’
Item 7 ‘I worry a lot’
Item 8 ‘I feel too guilty’
Figure 1. Items of the Young Adult Self-Report Scale, obsessive-
compulsive symptoms (YASR-OCS20).
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questionnaire.25 To determine the severity of depressive
symptoms the Inventory of Depressive Symptomatology
(IDS) was used, a 30-item self-report questionnaire.26 Both
scales have proven to be psychometrically valid and
reliable.27,28
Statistical Analyses
Participants with OCS were compared with those without
OCS on sociodemographics and on symptom severity using
2-tailed chi-square statistics for categorical variables and
1-way analysis of variance statistics (ANOVA) for contin-
uous variables. To examine the presence of OCS across
diagnostic groups (healthy controls, remitted anxiety and/
or depressive disorders, current anxiety disorder, current
depressive disorder, current comorbid disorder), 2-tailed
chi-square statistics were used. To examine whether the
presence of OCS in persons with a current disorder was
associated with the severity of these disorders as assessed
on the BAI and IDS, 1-way ANOVA statistics were used.
To evaluate the impact of OCS on course trajectories, we
defined subsamples. To study the impact of OCS on first
onset of anxiety and/or depressive disorders, we used the
subsample of healthy controls (n ¼ 469). First onset in the
healthy participants was defined as the presence of a diagno-
sis of anxiety and/or depressive disorder during the 2-year
follow-up period. To examine “relapse,” we selected 909
participants who were remitted at first assessment. Relapse
was defined as the presence of an anxiety and/or depressive
disorder in the past 6 months. To examine “persistence,”
participants with a current anxiety and/or depressive disorder
at first assessment were selected. Persistence was defined as
the 6-month presence of an anxiety and/or depressive disorder
at follow-up.
First, chi-square statistics were conducted to examine
whether course was more unfavorable in those with OCS
versus in those without OCS. Next, bivariate regression
analyses were conducted with onset, relapse, and persis-
tence as dependent variables. Independent variables
entailed the presence of OCS, gender, age, years of educa-
tion, and anxiety and depression symptom severity para-
meters. No other possible confounders were explored.
Finally, to assess whether OCS are independently associ-
ated with onset, relapse, and persistence of anxiety and/or
depressive disorders, multivariate analyses were con-
ducted, including all variables as covariates. P values
<0.05 were considered significant. All statistical analyses
were conducted with the SPSS statistical package version
20.0 (SPSS Inc., Chicago, IL).
Results
Sample Description
The sample consisted of 2125 participants with an average
age of 44.6 years (SD, 13.2), who were predominantly
female (66.7%) and had an average of 12.7 years of educa-
tion (SD, 3.3). The mean IDS score was 15.3 (SD, 11.8), and
the mean BAI score was 8.3 (SD, 8.4; see Table 1). Of the
total sample, 22.1% (n ¼ 469) were healthy controls, 42.8%
(n ¼ 909) had a remitted anxiety and/or depressive disorder,
9.6% (n ¼ 205) had a current depressive disorder, 12.7%
(n ¼ 270) had a current anxiety disorder, and 12.8% (n ¼
272) had a current comorbid anxiety and depressive disorder.
Presence of OCS
Using the predefined threshold on the YASR-OCS, 76.4% of
the sample (n ¼ 1624) did not have OCS (YASR-OCS  7),
whereas in the remaining 23.6% (n¼ 501), OCS were present
(YASR-OCS > 7). Participants with OCS were more likely to
be male and younger and to report fewer years of education. In
addition, the presence of OCS was associated with higher
levels of anxiety and depressive symptoms (see Table 1).
The correlations between the YASR-OCS and IDS and
between the YASR-OCS and BAI were 0.66 and 0.58,
respectively.
Association between Current Presence of OCS and
Presence and Severity of Anxiety and/or Depressive
Disorders
The presence of OCS was associated with the presence of
anxiety and depression; OCS were hardly present in healthy




(n ¼ 1624, 76.4%)
Presence of OCS
(n ¼ 501, 23.6%) w2/F (df) P
Sociodemographic factors
Age (mean, SD) 44.6 (13.2) 44.9 (13.2) 43.4 (12.9) 5.4 (1) 0.02
Gender (% female, n) 66.7 (1418) 67.9 (1102) 63.1 (216) 3.9 (1) 0.05
Education (mean number of years, SD) 12.7 (3.3) 12.7 (3.3) 12.4 (3.3) 4.5 (1) 0.04
Severity
IDS (mean, SD) 15.3 (11.8) 11.7 (9.3) 26.6 (11.8) 862.7 (1) <0.0001
BAI (mean, SD) 8.3 (8.4) 6.2 (6.7) 15.2 (9.6) 556.5 (1) <0.0001
aThe presence of OCS was defined as scores on the YASR-OCS > 7. IDS ¼ Inventory of Depressive Symptomatology26; BAI ¼ Beck Anxiety Inventory25;
YASR-OCS ¼ Young Adult Self-Report Scale, obsessive-compulsive symptoms.20
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controls, were infrequently present in remitted patients, and
were predominantly present in those with current anxiety
and/or depressive disorders, w2: 473.74 (df 4), P < 0.001.
Results are presented in Figure 2.
More specifically, among participants with a current dis-
order, the presence of OCS was associated with severity of
the current disorder. Thus, in participants with a current
depressive disorder, those with OCS had higher mean IDS
scores than those without OCS (IDS 26.4 [SD, 11.0] vs 20.3
[SD, 10.8]; F 15.07 [df 1], P < 0.001). Likewise, in partici-
pants with an anxiety disorder, those with OCS had higher
mean BAI scores as compared with those without OCS (BAI
14.5 [SD, 8.5] vs 11.8 [SD, 8.7]; F 5.95 [df 1], P ¼ 0.02).
Also, in participants with a comorbid anxiety and depressive
disorder, both IDS and BAI scores were significantly higher
in those with OCS as compared with those without OCS
(IDS: 33.7 [SD, 11.5] vs 24.7 [SD, 10.7]; F 39.86 [df 1],
P < 0.001, and BAI: 20.3 [SD, 10.0] vs 13.4 [SD, 8.4];
F 31.22 [df 1], P < 0.001).
Predictive Value of OCS on First Onset and 2-Year
Course Trajectories of Anxiety and Depressive Disorders
First onset of anxiety and depressive disorders at 2-year
follow-up occurred in 4.5% (n ¼ 21) of the healthy controls
and was associated with presence of OCS. Relapse within
2 years occurred in 19.5% (n ¼ 177) of the participants with
a remitted disorder at baseline. Relapse was significantly
associated with OCS as well. The baseline disorder persisted
in the 2-year follow-up period in 41.0% (n ¼ 84) of partici-
pants with a depressive disorder, in 51.1% (n¼ 138) of those
with anxiety disorders, and in 70.6% (n ¼ 192) of the parti-
cipants with a comorbid anxiety and depressive disorder.
Persistence was significantly associated with the presence
of OCS above the cut point in participants with a comorbid
anxiety and depressive disorder but not in those with a single
anxiety or depressive disorder. Results are presented in Table 2.
Table 3 presents the association between OCS, sociode-
mographic factors, symptom severity, and the presence of an
anxiety and/or depressive disorder at follow-up. In healthy
controls who developed an anxiety and/or depressive disor-
der (n ¼ 21), only 2 showed OCS above cut point (OR, 5.79;
95% CI, 1.15 to 29.14; see Table 3). Post hoc analysis
showed that the 21 participants who developed a disorder
showed significantly higher mean YASR-OCS scores at
baseline than the healthy controls who did not develop a
disorder (mean YASR-OCS score 3.1 vs 1.4; F: 18.02 [df
1], P < 0.0001), suggesting that OCS in healthy controls are
associated with development of anxiety or depressive disor-
ders in the 2-year follow-up period.
In participants with a remitted disorder, OCS were signif-
icantly associated with relapse (OR, 3.10; 95% CI, 2.13 to
4.50), but the association lost significance after adjusting for
severity of anxiety and depressive symptoms.
As mentioned above, in single depressive and anxiety
disorders, OCS were not significantly associated with per-
sistence (OR, 1.38; 95% CI, 0.77 to 2.45 and OR, 1.03; 95%
CI, 0.63 to 1.69, respectively), but in comorbid anxiety and
depressive disorders, they were significantly associated with
persistence (OR, 4.42; 95% CI, 2.54 to 7.70). This finding
remained significant when adjusting for severity of anxiety
and depressive symptoms (OR, 3.49; 95% CI, 1.88 to 6.07).
Discussion
No prior research has systematically examined the impact of
comorbid OCS on clinical outcomes in anxiety disorders,
and OCS impact has been studied in only one study in
depressive disorders. Generally, our findings are in line with
previous research indicating that comorbidity in anxiety and
depressive disorders in general is associated with severity
and chronicity3-5,9,29 and, more specifically, in depressive
disorders, indicating that comorbid OCS is associated with
poorer outcome.18 Our findings implicate that OCS comor-
bidity may be a valuable specifier of outcome in both anxiety
and depressive disorders, in line with findings of comorbid
anxiety symptoms in depression and panic attacks across the
full range of psychopathology that predict worse out-
come.14,16 For example, we found that relapse occurred in
one-fifth of our sample. Given this high rate, which is con-
sistent with relapse rates found in previous research on anxi-
ety and depression comorbidities,8,30 identifying patients at
high risk for relapse is of utmost importance. Especially in
anxiety disorders, predictors of relapse have been scarcely
identified.31 Our finding that OCS predicted relapse in anxi-
ety and depression disordered patients means that standard
screening for these patients with obsessive-compulsive
symptomatology might be helpful to identify those at a
higher risk for relapse. In this exploratory study on the rela-
tionship between OCS on one hand and anxiety and depres-




































Figure 2. Presence of obsessive-compulsive symptoms (OCS)
across healthy controls, participants with a remitted anxiety and/
or depressive disorder, and participants with a current anxiety and/
or depressive disorder (N ¼ 2125). Presence of OCS was defined
as scores on the YASR-OCS > 7. YASR-OCS ¼ Young Adult Self-
Report Scale, obsessive-compulsive symptoms.20 Overall statistics:
w2: 473.74(df ¼ 4), P < 0.001.
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were present in a substantial proportion of participants with
current anxiety and/or depressive disorders and was more-
over associated with higher symptom severity of these dis-
orders. In addition, OCS predicted first onset of anxiety and/
or depressive disorder, relapse of anxiety and/or depressive
disorders, and persistence in those with a comorbid anxiety
and depressive disorder. Our results suggest that OCS does
not predict relapse independently of anxiety and depression
severity. This can be partially explained by symptom overlap
between the measurement instrument for OCS on one hand
(YASR-OCS) and anxiety and depression severity on the
other; that is, correlations between the YASR-OCS and
questionnaires used to assess severity of depression and
anxiety were, respectively, 0.66 (between YASR-OCS and
IDS) and 0.58 (between YASR-OCS and BAI). One might
argue that OCS, anxiety, and depression share symptom
overlap and that, as such, comorbid OCS are merely markers
of symptom severity, which is by and of itself a predictor of
worse outcome, rather than these findings suggesting a spe-
cific OCS-based prediction effect of worse outcome. In other
words, rather than considering OCD, anxiety disorders, and
depression as distinct disorders, which the original definition
of comorbidity requires,32 this type of comorbidity might be
regarded as a correlate for severity of the index disorder.
However, the finding that OCS predicted persistence in
comorbid anxiety and depressive disorder independent of
(and maybe even more than) severity of anxiety and depres-
sion argues against this line of reasoning and suggests that
OCS also have specific unfavorable effects that do not over-
lap with general aspects of anxiety and depression. One
drawback of the YASR-OCS, used to measure OCS, is that
this instrument, although accurate in its sensitivity to detect
OCS both in children and in adults,20,21 has little specificity
with respect to OC item content. As such, a more specific
OC item containing self-report instruments, such as the
Obsessive-Compulsive Inventory–Revised,33 might suffer
less from item overlap and be more useful for investigating
the specificity of the unfavorable effect of OCS on outcome
in anxiety and depressive disorders. In all, these findings of
clear associations between OCS, and new onset, relapse, and
(in comorbid cases) persistence in anxiety and depressive
disorders suggest a role for OCS both as a marker of severity
and as a specific OCS effect. With respect to a specific OCS-
related effect, whether this is the result of a lack of flexibility
to change and—as a consequence—decreased ability to
profit from therapy in OCD associated with specific execu-
tive and neurobiological dysfunctions has not been
addressed in this project.32 However, future studies on this
topic, coupled with intervention strategies that specifically
target OC symptoms in anxiety and depressive disordered
patients at an early stage of disease development, can direct
new treatment avenues.
Several strengths and limitations should be taken into
account. Strengths include the large sample size, the well-
implemented design of the NESDA study, and the longitudi-
nal design. Three limitations should be acknowledged as well.
First, as OCS were first assessed at the second wave of
NESDA, we had no other option than to use this as our
baseline measurement. This may have influenced results,
as attrition and exclusion rates were somewhat selective.
Second, we assessed OCS with the YASR-OCS and used
a cutoff score >7 to define the presence of clinically signif-
icant OCS. Because the diagnosis of OCD has not been
assessed in NESDA, we cannot be certain whether partici-
pants scoring above the threshold on the YASR-OCS had in
fact subthreshold symptoms or fulfilled criteria of obsessive-
compulsive disorder. However, the cutoff score of the
YASR-OCS used in the present study provides a reasonable
sensitivity of 82.4% to predict presence of OCD19 in the
current sample. On the other hand, given the specificity of
Table 2. Impact of Obsessive Compulsive Symptoms (OCS) on the 2-Year Course Trajectory of Healthy Controls and Participants with





OCS (%, n) w2 (df) P
First onset (in healthy controls, n ¼ 469)
First onset (n ¼2 1)






Relapse (in participants with a remitted anxiety and/or depressive disorder, n ¼ 909)
Relapse (n ¼ 177)






Persistence (in participants with a depressive disorder, n ¼ 205)
Persistence (n ¼ 84)






Persistence (in participants with an anxiety disorder, n ¼ 270)
Persistence (n ¼ 138)






Persistence (in participants with an anxiety and depressive disorder, n ¼ 272)
Persistence (n ¼ 192)






aPresence of OCS was defined as scores on the YASR-OCS > 7. YASR-OCS ¼ Young Adult Self-Report Scale, obsessive-compulsive symptoms.20
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69.7%, the YASR-OCS has a relatively high chance of false-
positive findings.19 Because persons with a primary diagno-
sis of OCD were not included in NESDA, we assume that the
majority of participants scoring above the threshold had
either subthreshold symptoms or had OCD but regarded this
as a secondary problem. In all, it seems justified to conclude
that a substantial level of OCS has a substantial predictive
value. When generalizing these results to populations with
comorbid OCD, it is likely that the negative effect of comor-
bid OCD is even larger than the results presented here.
Third, we used the term persistence to describe an unfa-
vorable course trajectory, defined as the presence of a dis-
order at 2-year follow-up. This definition has not taken into
account the in-between trajectory and—might be—remis-
sion proportions in between and therefore should be
regarded as a rather rough measure of persistence.
Finally, because of limited numbers of participants with a
first onset of an anxiety or depressive disorder, conclusions
regarding first onset should be regarded preliminary.
Clinical Implications and Conclusion
OCS frequently co-occur in populations with anxiety and
depressive disorders as a primary diagnosis. Although pres-
ent, OCS might be unnoticed or unreported by patients
because the focus of attention is on the primary diagnoses.
However, as OCS seem to unfavorably influence course, it
seems important to treat these symptoms from the early
treatment stages on. What are adequate treatments of comor-
bid OCS? No pharmacological trials, to our knowledge, have
specifically addressed this question. On the contrary, most
studies exclude patients with OCS comorbidity. Thus, no
evidence-based statements for the pharmacological treat-
ment of comorbidity can be made at this time. There is
growing, but contradicting, research on psychological treat-
ment of comorbidity. Some research suggests that by treating
the primary diagnosis, comorbid symptoms also decline.34-36
Although this might be the case, the presence of residual
symptoms (not a full recovery of the comorbid disorder) is
an important risk factor for relapse of the comorbid disor-
der.37 Other research shows that simultaneous application of
more than one disorder-specific cognitive behavioral therapy
(CBT) does not seem to enhance treatment outcome.38 Cur-
rent research focusses on a new form of CBT:
“transdiagnostic treatment.” This form of CBT targets more
than one diagnosis by, for example, focusing on regulating
emotions.39-42
Apart from the discussion of adequate treatment of
comorbid OCS, OCS may thus serve as a specifier in clinical
practice distinguishing between patients with mild disorders
and favorable course trajectories and patients with severe
disorders and unfavorable course trajectories. Since patients
do not report these symptoms by themselves, the presence of
OCS might be easily missed in clinical practice.43 Clinicians
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Administering a standard self-report questionnaire such as
the YASR-OCS might help clinicians in their assessment.
To conclude, knowledge from the present study may add
to models for profiling and staging of anxiety and depressive
disorders that are currently being developed order to
improve clinical prediction and to direct treatment.44-47
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